Matthew Fomonyuy Yuyun, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cardiac Resynchronization Therapy | 4 | 2024 | 555 | 1.340 |
Why?
|
Defibrillators, Implantable | 5 | 2024 | 1490 | 1.130 |
Why?
|
Albuminuria | 6 | 2005 | 658 | 1.030 |
Why?
|
Adrenomedullin | 2 | 2017 | 85 | 1.030 |
Why?
|
Mitral Valve Insufficiency | 2 | 2024 | 1400 | 0.920 |
Why?
|
Arrhythmias, Cardiac | 6 | 2023 | 2244 | 0.880 |
Why?
|
Heart Failure | 8 | 2024 | 11671 | 0.860 |
Why?
|
Bradycardia | 3 | 2020 | 299 | 0.820 |
Why?
|
Pacemaker, Artificial | 2 | 2024 | 807 | 0.720 |
Why?
|
Atrial Fibrillation | 5 | 2024 | 5127 | 0.700 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2024 | 353 | 0.690 |
Why?
|
Atrioventricular Block | 2 | 2018 | 133 | 0.660 |
Why?
|
Death, Sudden, Cardiac | 3 | 2022 | 1555 | 0.620 |
Why?
|
Sick Sinus Syndrome | 1 | 2018 | 44 | 0.600 |
Why?
|
Tetrahydrofolates | 1 | 2018 | 58 | 0.590 |
Why?
|
Electric Countershock | 1 | 2021 | 533 | 0.590 |
Why?
|
Stroke Volume | 4 | 2024 | 5496 | 0.560 |
Why?
|
Ventricular Function, Left | 3 | 2024 | 3879 | 0.520 |
Why?
|
Device Removal | 1 | 2021 | 630 | 0.520 |
Why?
|
Cardiac Pacing, Artificial | 3 | 2024 | 866 | 0.420 |
Why?
|
Primary Dysautonomias | 2 | 2022 | 28 | 0.410 |
Why?
|
Cardiovascular Diseases | 8 | 2021 | 15502 | 0.400 |
Why?
|
Nitric Oxide | 1 | 2018 | 2135 | 0.320 |
Why?
|
Cause of Death | 3 | 2024 | 3683 | 0.320 |
Why?
|
Africa South of the Sahara | 3 | 2020 | 744 | 0.320 |
Why?
|
Myocardial Infarction | 4 | 2017 | 11461 | 0.290 |
Why?
|
Hemodynamics | 1 | 2018 | 4160 | 0.290 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2022 | 12149 | 0.260 |
Why?
|
Retinal Diseases | 2 | 2022 | 705 | 0.260 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4431 | 0.260 |
Why?
|
Catheter Ablation | 2 | 2023 | 2751 | 0.260 |
Why?
|
Hypoglycemia | 2 | 2022 | 883 | 0.240 |
Why?
|
Morbidity | 2 | 2020 | 1751 | 0.240 |
Why?
|
Risk Factors | 17 | 2024 | 74212 | 0.230 |
Why?
|
Hospitalization | 1 | 2024 | 10721 | 0.230 |
Why?
|
Genital Diseases, Male | 1 | 2004 | 83 | 0.220 |
Why?
|
Prognosis | 7 | 2024 | 29629 | 0.200 |
Why?
|
Survival Rate | 4 | 2023 | 12725 | 0.190 |
Why?
|
Diabetic Neuropathies | 1 | 2003 | 405 | 0.160 |
Why?
|
Incidence | 7 | 2022 | 21355 | 0.160 |
Why?
|
Cardiology | 2 | 2020 | 1656 | 0.160 |
Why?
|
Humans | 39 | 2024 | 761578 | 0.160 |
Why?
|
Stroke | 4 | 2024 | 9758 | 0.150 |
Why?
|
Long QT Syndrome | 1 | 2022 | 467 | 0.150 |
Why?
|
Urinary Tract Infections | 1 | 2004 | 802 | 0.150 |
Why?
|
Education | 1 | 2020 | 537 | 0.140 |
Why?
|
Developed Countries | 1 | 2020 | 449 | 0.140 |
Why?
|
Middle Aged | 22 | 2024 | 220917 | 0.140 |
Why?
|
Minority Groups | 2 | 2020 | 1203 | 0.130 |
Why?
|
Atrial Flutter | 1 | 2018 | 252 | 0.130 |
Why?
|
Heart Rate | 3 | 2022 | 4195 | 0.120 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 973 | 0.120 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2018 | 705 | 0.120 |
Why?
|
Prevalence | 4 | 2024 | 15732 | 0.120 |
Why?
|
Homocysteine | 1 | 2018 | 638 | 0.120 |
Why?
|
Time Factors | 4 | 2024 | 39970 | 0.120 |
Why?
|
Aged | 14 | 2024 | 169308 | 0.110 |
Why?
|
Risk Assessment | 5 | 2024 | 23996 | 0.110 |
Why?
|
Action Potentials | 1 | 2021 | 1834 | 0.110 |
Why?
|
Autonomic Nervous System | 3 | 2022 | 703 | 0.100 |
Why?
|
Male | 22 | 2024 | 360841 | 0.100 |
Why?
|
Electric Power Supplies | 1 | 2013 | 96 | 0.100 |
Why?
|
Electrocardiography | 4 | 2022 | 6377 | 0.100 |
Why?
|
Primary Prevention | 1 | 2020 | 1186 | 0.100 |
Why?
|
Female | 22 | 2024 | 392688 | 0.100 |
Why?
|
Lyme Disease | 1 | 2018 | 631 | 0.100 |
Why?
|
Predictive Value of Tests | 4 | 2015 | 15266 | 0.090 |
Why?
|
Income | 1 | 2020 | 1877 | 0.090 |
Why?
|
Folic Acid | 1 | 2018 | 1323 | 0.090 |
Why?
|
England | 3 | 2014 | 526 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6484 | 0.090 |
Why?
|
Proportional Hazards Models | 4 | 2017 | 12463 | 0.090 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12059 | 0.090 |
Why?
|
Plaque, Atherosclerotic | 1 | 2021 | 1532 | 0.090 |
Why?
|
Heart Diseases | 1 | 2022 | 2781 | 0.080 |
Why?
|
Treatment Outcome | 4 | 2023 | 64684 | 0.080 |
Why?
|
Coronary Disease | 1 | 2004 | 5914 | 0.080 |
Why?
|
Veterans | 1 | 2023 | 2649 | 0.080 |
Why?
|
Age Distribution | 2 | 2004 | 2879 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2024 | 58983 | 0.070 |
Why?
|
Oxidative Stress | 1 | 2018 | 3113 | 0.070 |
Why?
|
Adult | 16 | 2022 | 221200 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2018 | 1852 | 0.070 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2014 | 993 | 0.070 |
Why?
|
Hydrocortisone | 1 | 2014 | 1819 | 0.060 |
Why?
|
Blood Pressure | 1 | 2021 | 8481 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2018 | 3415 | 0.060 |
Why?
|
Heart | 3 | 2022 | 4404 | 0.060 |
Why?
|
Cameroon | 1 | 2004 | 76 | 0.060 |
Why?
|
Urethral Stricture | 1 | 2004 | 50 | 0.060 |
Why?
|
Heart Arrest | 1 | 2014 | 1514 | 0.060 |
Why?
|
Registries | 1 | 2020 | 8224 | 0.060 |
Why?
|
Coronary Artery Disease | 1 | 2021 | 6403 | 0.050 |
Why?
|
Prospective Studies | 5 | 2022 | 54423 | 0.040 |
Why?
|
Morocco | 1 | 2020 | 30 | 0.040 |
Why?
|
Electrophysiology | 1 | 2023 | 1262 | 0.040 |
Why?
|
Africa, Northern | 1 | 2020 | 86 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5971 | 0.040 |
Why?
|
Prostatic Hyperplasia | 1 | 2004 | 521 | 0.040 |
Why?
|
Sex Distribution | 1 | 2004 | 2280 | 0.040 |
Why?
|
Cardiology Service, Hospital | 1 | 2020 | 239 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2005 | 1315 | 0.040 |
Why?
|
Renal Insufficiency | 1 | 2004 | 809 | 0.040 |
Why?
|
Africa | 1 | 2020 | 709 | 0.040 |
Why?
|
Cohort Studies | 4 | 2022 | 41493 | 0.040 |
Why?
|
Capacity Building | 1 | 2020 | 258 | 0.040 |
Why?
|
Ceftriaxone | 1 | 2018 | 175 | 0.030 |
Why?
|
Recurrence | 2 | 2023 | 8466 | 0.030 |
Why?
|
Temperature | 1 | 2023 | 2226 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2023 | 80646 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17904 | 0.030 |
Why?
|
Doxycycline | 1 | 2018 | 344 | 0.030 |
Why?
|
Hyperglycemia | 1 | 2004 | 1376 | 0.030 |
Why?
|
HIV Infections | 1 | 2021 | 17352 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 23447 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2021 | 39107 | 0.030 |
Why?
|
Hypertension | 2 | 2005 | 8540 | 0.030 |
Why?
|
Wales | 1 | 2014 | 87 | 0.030 |
Why?
|
South Africa | 1 | 2020 | 1843 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2004 | 6815 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2006 | 5492 | 0.030 |
Why?
|
Mass Screening | 2 | 2006 | 5428 | 0.030 |
Why?
|
Medical Audit | 1 | 2014 | 453 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1403 | 0.030 |
Why?
|
Odds Ratio | 1 | 2004 | 9646 | 0.020 |
Why?
|
Administration, Oral | 1 | 2020 | 4021 | 0.020 |
Why?
|
Developing Countries | 1 | 2004 | 2885 | 0.020 |
Why?
|
Ventricular Fibrillation | 1 | 2014 | 537 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2013 | 15633 | 0.020 |
Why?
|
Animals | 1 | 2022 | 168475 | 0.020 |
Why?
|
Sex Factors | 1 | 2004 | 10554 | 0.020 |
Why?
|
Exercise Test | 1 | 2018 | 2127 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2022 | 3085 | 0.020 |
Why?
|
Logistic Models | 1 | 2004 | 13255 | 0.020 |
Why?
|
Calcium | 1 | 2021 | 5722 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3415 | 0.020 |
Why?
|
Smoking | 1 | 2004 | 9053 | 0.020 |
Why?
|
Age Factors | 1 | 2004 | 18398 | 0.020 |
Why?
|
Patient Admission | 1 | 2014 | 1367 | 0.020 |
Why?
|
Echocardiography | 1 | 2018 | 4989 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 4125 | 0.010 |
Why?
|
Anticoagulants | 1 | 2020 | 4812 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2004 | 26127 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12973 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10090 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2004 | 11122 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2006 | 1258 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2014 | 5293 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 2006 | 14665 | 0.010 |
Why?
|
Area Under Curve | 1 | 2004 | 1638 | 0.010 |
Why?
|
Patient Readmission | 1 | 2014 | 3271 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7406 | 0.010 |
Why?
|
ROC Curve | 1 | 2004 | 3578 | 0.010 |
Why?
|
Adolescent | 1 | 2004 | 88323 | 0.010 |
Why?
|
Neoplasms | 1 | 2004 | 22172 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2006 | 3575 | 0.010 |
Why?
|
Health Surveys | 1 | 2004 | 4061 | 0.010 |
Why?
|
Blood Glucose | 1 | 2004 | 6391 | 0.010 |
Why?
|